Seeking Alpha

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (RXRX) (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...
Seeking Alpha

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024 Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, which ...